|
Early Years Cook's Training
Grub4life offer a range of specialist cookery master classes and ...
|
|
|
|
The clinical effectiveness and cost effectiveness of sibutramine for obesity
NICE has recommended that sibutramine should be prescribed only as part of an overall treatment plan for the management of obesity for people aged 18-65 years who: 25-12-2006
have a body mass index (BMI) of 27.0 kg/m2 or more as well as other significant diseases (for example, type 2 diabetes, high cholesterol) have a BMI of 30.0 kg/m2 or more have made serious attempts to lose weight by dieting, exercise and/or other changes in their behaviour. Sibutramine should not be prescribed unless the person taking it has regular checks to measure their weight loss and to see if the medicine is causing any other problems (side effects). People taking sibutramine should only continue with treatment for more than 4 weeks if they have lost 2 kg in weight. People should only continue on this treatment beyond 3 months if they have lost at least 5% (5kg for each 100kg) of their body weight from the start of the drug treatment. Sibutramine should be stopped if patients do not lose weight as described above. Because sibutramine can cause increases in blood pressure, people taking it should have their blood pressure checked regularly. Increases in blood pressure should be considered carefully, and may be a reason to stop treatment. Sibutramine is not recommended for patients who already have high blood pressure (145/90 or above). Treatment is not recommended for more than 12 months. There is no evidence to show that prescribing sibutramine with other drugs used to treat obesity has any benefits for the person with obesity. Source – The National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health. www.nice.org.uk
|
|
|
|
|
|
|
